With sales of more than $22 billion, Abbott’s broad product portfolio addresses critical needs across the $2 trillion health care market.

At the number-three position in the nearly $10 billion vascular care market, Abbott has the potential to become a leader with Xience V, a next-generation drug-eluting stent.

By 2030, 360 million people worldwide are expected to be living with diabetes — twice as many as today. Abbott is a leader in diabetes care, with the world’s smallest blood glucose meter, delivering rapid test results.

With $2 billion in annual sales just four years after approval, Humira shows great promise in treating several additional autoimmune diseases in the years to come.

Abbott nutritional products, such as Similac Advance for infants and Ensure for adults, are growing rapidly in emerging markets such as China, where sales increased more than 100 percent in 2006.

Abbott competes in the nearly $20 billion cholesterol market — the largest U.S. pharmaceutical market — with TriCor and Niaspan, and is developing three additional cholesterol compounds.

Abbott Molecular Diagnostics is one of the fastest-growing molecular businesses in a market that is expected to double with the mapping of the human genome now complete.